Responsible for directly selling CRO services to potential or existing clients within the Western US and Western Canada region. Working to build key client partnerships for growing the CRO clinical trial business. Actively supporting the marketing, advertising, and market research of clinical trial services. Coordination of customer interactions including presentations and meetings with clinical operations and the internal selling support team. Creation of feasibility reports, proposals and contracts as needed.

Responsible for directly selling CRO services to potential or existing clients within the Western US and Western Canada region. Working to build key client partnerships for growing the CRO clinical trial business. Actively supporting the marketing, advertising, and market research of clinical trial services. Coordination of customer interactions including presentations and meetings with clinical operations and the internal selling support team. Creation of feasibility reports, proposals and contracts as needed. deCODE chemistry and biostructures January, 2008-August, 2008 Identification of new clients and business opportunities with large pharmaceutical and biotech companies while growing existing client accounts. Attendance at client meetings, trade shows and conferences to promote services for structural biology, medicinal chemistry, process chemistry, analytical chemistry, parallel protein purification and analysis, protein-ligand co-crystal structure determination, high throughput crystallization screening, X-ray data collection, computer aided design of expression-optimized synthetic genes, formulation development, physicochemical characterization, pre-formulation screening, lead optimization, In Silico hit optimization, drug safety, drug metabolism, in vitro ADME and toxicology, safety and toxicology studies. Currently working with internal marketing and scientific operations groups to generate business proposals. Also responsible for cold calling, negotiation of contracts, and business plan development. Territory includes New England, Mid-Atlantic and the Southeast.

deCODE Chemistry and Biostructures January, 2008-August, 2008 Identification of new clients and business opportunities with large pharmaceutical and biotech companies while growing existing client accounts. Attendance at client meetings, trade shows and conferences to promote services for structural biology, medicinal chemistry, process chemistry, analytical chemistry, parallel protein purification and analysis, protein-ligand co-crystal structure determination, high throughput crystallization screening, X-ray data collection, computer aided design of expression-optimized synthetic genes, formulation development, physicochemical characterization, pre-formulation screening, lead optimization, In Silico hit optimization, drug safety, drug metabolism, in vitro ADME and toxicology, safety and toxicology studies. Worked with internal marketing and scientific operations groups to generate business proposals. Also responsible for cold calling, negotiation of contracts, and business plan development. Territory included New England, Mid-Atlantic and the Southeast. Parent company, deCODE Genetics delisted from NASDAQ.

Responsibilities included clinical support for a Ph II clinical trial for a Class III transdermal medical device that used ultrasound to deliver insulin to patients with Type 2 diabetes. Preclinical trial oversight responsibilities included compound optimization, structural biology, formulation development and outsourcing of analytical, API, medicinal and process chemistry support services. Marketing efforts included growing the business through professional, consultative and proactive sales activities with key physician decision makers and decision influencers, as well as acting as the liaison between biotech, pharmaceutical and other medical device companies and ESI. Directly responsible for oversight of the Scientific Advisory Board and management of all SAB meetings. Directly responsible for P&L activities and management of four clinical and four BD team members. Current activities included identifying and developing potential business partners and growing existing client relationships, generating new business, establishing and executing a comprehensive sales plan for the region, planning and coordinating all client sales activities, and representing ESI at client meetings, local, national and international diabetes public speaking events, exhibits, diabetes trade shows and diabetes conferences. Other activities include managing and integrating all activities with Medical Affairs, Medical Communications, Publications, Medical Education, Clinical Operations (CRAs, Project Directors), Finance, Proposals & Contracts and Marketing. Lost VC funding and all employees laid off.

Responsibilities included clinical support for a Ph II clinical trial for a Class III transdermal medical device that used ultrasound to deliver insulin to patients with Type 2 diabetes. Preclinical trial oversight responsibilities included compound optimization, structural biology, formulation development and outsourcing of analytical, API, medicinal and process chemistry support services. Marketing efforts included growing the business through professional, consultative and proactive sales activities with key physician decision makers and decision influencers, as well as acting as the liaison between biotech, pharmaceutical and other medical device companies and ESI. Directly responsible for oversight of the Scientific Advisory Board and management of all SAB meetings. Directly responsible for P&L activities and management of four clinical and four BD team members. Current activities included identifying and developing potential business partners and growing existing client relationships, generating new business, establishing and executing a comprehensive sales plan for the region, planning and coordinating all client sales activities, and representing ESI at client meetings, local, national and international diabetes public speaking events, exhibits, diabetes trade shows and diabetes conferences. Other activities include managing and integrating all activities with Medical Affairs, Medical Communications, Publications, Medical Education, Clinical Operations (CRAs, Project Directors), Finance, Proposals & Contracts and Marketing.

Was responsible for new business development within PAREXEL’s medical communications group: meetings, posters, publications, events, branding, interactive media, competitive intelligence and conferences. Activities included identifying new leads, coordinating business pitches, acting as a primary liaison with new pharmaceutical, biotech and device clients while working with Vice Presidents, Directors and Associate Directors of Business Development. Responsible for developing and expanding business opportunities beyond established accounts and moving into a wider range of markets: vaccines, -3-small emerging biotech companies, government and advocacy groups. Frequent representation at relevant conferences, tradeshows and conventions. Cultivation of strong relationships with existing client decision makers includes development of strategic, detailed business plans for Ph III and IV pre-launch, launch and post launch medical communications support. Working with Vice President of Business Development to lead the entire sales process, complete each proposal, and negotiation of contracts.

Was responsible for new business development within PAREXEL's medical communications group: meetings, posters, publications, events, branding, interactive media, competitive intelligence and conferences. Activities included identifying new leads, coordinating business pitches, acting as a primary liaison with new pharmaceutical, biotech and device clients while working with Vice Presidents, Directors and Associate Directors of Business Development. Responsible for developing and expanding business opportunities beyond established accounts and moving into a wider range of markets: vaccines, -3-small emerging biotech companies, government and advocacy groups. Frequent representation at relevant conferences, tradeshows and conventions. Cultivation of strong relationships with existing client decision makers includes development of strategic, detailed business plans for Ph III and IV pre-launch, launch and post launch medical communications support. Working with Vice President of Business Development to lead the entire sales process, complete each proposal, and negotiation of contracts.

Sales and marketing of protein tomography molecular imaging to pharmaceutical, diagnostic and biotech companies within the US and Canada. Sales activities include cold calling, follow up letters, proposal writing, convention participation, capabilities, public speaking and bid defense negotiations. Worked with sales counterparts in the US and Europe to drive marketshare in the US and Canada. Was responsible for all sales and marketing activities to pharmaceutical and biotech vice president and director level key decision makers. Contributed to Stockholm scientific and sales teams’ efforts to help develop proposals, bids and contracts while expanding and maintaining all customer accounts. Major sales to MedImmune, Human Genome Sciences, Merck, University of Toronto and Alexion Pharmaceuticals worth approximately $600,000. Consultancy contract ended 12-15-05.

Sales and marketing of protein tomography molecular imaging to pharmaceutical, diagnostic and biotech companies within the US and Canada. Sales activities include cold calling, follow up letters, proposal writing, convention participation, capabilities, public speaking and bid defense negotiations. Worked with sales counterparts in the US and Europe to drive marketshare in the US and Canada. Was responsible for all sales and marketing activities to pharmaceutical and biotech vice president and director level key decision makers. Contributed to Stockholm scientific and sales teams' efforts to help develop proposals, bids and contracts while expanding and maintaining all customer accounts. Major sales to MedImmune, Human Genome Sciences, Merck, University of Toronto and Alexion Pharmaceuticals worth approximately $600,000. Consultancy contract ended 12-15-05.

Responsible for directly selling CRO services and product launch programs to potential or existing clients within the Mid Atlantic region including New Jersey, New York and Pennsylvania. Worked to build key client partnerships for growing the CRO and product launch businesses. Actively supported the marketing, advertising, market research and market communications departments of this CRO. Coordinated customer interactions including presentations and meetings with clinical operations and the internal selling support team. Supervised and mentored three administrative assistants, two proposal writers and two sales associates. Reviewed and approved proposals as needed. Closed $3 million in CRO sales and developed additional bids worth $15 million. Represented Premier Research at all conferences, medical events, and industry conventions. Downsized after CRC acquisition.

Responsible for directly selling CRO services and product launch programs to potential or existing clients within the Mid Atlantic region including New Jersey, New York and Pennsylvania. Worked to build key client partnerships for growing the CRO and product launch businesses. Actively supported the marketing, advertising, market research and market communications departments of this CRO. Coordinated customer interactions including presentations and meetings with clinical operations and the internal selling support team. Supervised and mentored three administrative assistants, two proposal writers and two sales associates. Reviewed and approved proposals as needed. Closed $3 million in CRO sales and developed additional bids worth $15 million. Represented Premier Research at all conferences, medical events, and industry conventions. Downsized after CRC acquisition.

Sales of Phase I to Phase IV clinical trials support: data management, biostatistics, patient registries, medical monitoring, IVRS, regulatory affairs and clinical support. Closed $2 million in sales and developed $20 million in bids for a northern NJ biotech company. Worked with cross-functional teams to develop proposals, bids and sales of patient registries, regulatory support and data management services. Maintained biotech and pharmaceutical clients in the northeastern United States while developing new clients as well. Contributed to financial bottom line and marketing efforts. Trained, supervised, and mentored two proposal writers and three administrative assistants. Downsized after company was acquired by Inveresk.

Sales of Phase I to Phase IV clinical trials support: data management, biostatistics, patient registries, medical monitoring, IVRS, regulatory affairs and clinical support. Closed $2 million in sales and developed $20 million in bids for a northern NJ biotech company. Worked with cross-functional teams to develop proposals, bids and sales of patient registries, regulatory support and data management services. Maintained biotech and pharmaceutical clients in the northeastern United States while developing new clients as well. Contributed to financial bottom line and marketing efforts. Trained, supervised, and mentored two proposal writers and three administrative assistants. Downsized after company was acquired by Inveresk.

Maintained and developed pharmaceutical clients. Contributed to annual sales per target objective while supporting the corporate budget. Recruited new business clients. Aligned Business Development objectives with overall corporate positioning. Worked with sales and marketing departments to design overall marketing plans, strategies, negotiations and tactics for pharmaceutical clients. Developed Business Development staff (administrative assistants, proposal writers, sales associates and data management associates) by mentoring, managing and training. Contributed as a Covance team member to pharmaceutical business proposal presentations

Maintained and developed pharmaceutical clients. Contributed to annual sales per target objective while supporting the corporate budget. Recruited new business clients. Aligned Business Development objectives with overall corporate positioning. Worked with sales and marketing departments to design overall marketing plans, strategies, negotiations and tactics for pharmaceutical clients. Developed Business Development staff (administrative assistants, proposal writers, sales associates and data management associates) by mentoring, managing and training. Contributed as a Covance team member to pharmaceutical business proposal presentations. Downsized.

Responsible for the scientific and sales training of 20 field sales representatives on a national basis. Responsibilities also included physician office, hospital, retail and managed care sales calls as a Senior Territory Manager. Responsible for 246 physicians including cardiologists, internists, general practitioners and family practitioners. Training program was eliminated.

Developed key regional and state physician advocates for Singulair, a new leukotriene receptor antagonist for asthma. Responsibilities included pre-launch calls to 125 key physicians as well as key hospital accounts. Trained 12 Merck field sales representatives on Singulair product knowledge as well as arranged all preceptorships and tutorials for pulmonary medicine with regional thought leaders for these representatives as well. Singulair MSL positions were transferred to Hospital Sales Representatives.

Key account development of cardiovascular, asthma and oncology drugs: Tenormin, Zestril, Sular, Accolate and Zolodex. Successful launch of new calcium channel blocker, Sular and leukotriene receptor antagonist, Accolate. Increased sales for cardiovascular products by 30%. Left AstraZeneca for Merck because of a substantially larger compensation package.